These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3525053)

  • 1. Prevalence of insulin deficiency among initially non-insulin-dependent middle-aged diabetic individuals.
    Laakso M; Sarlund H; Pyörälä K
    Diabetes Care; 1986; 9(3):228-31. PubMed ID: 3525053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with fasting and postglucagon plasma C-peptide levels in middle-aged insulin-treated diabetic patients.
    Laakso M; Rönnemaa T; Sarlund H; Pyörälä K; Kallio V
    Diabetes Care; 1989 Feb; 12(2):83-8. PubMed ID: 2649329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of fasting hyperglycemia and known non-insulin-dependent diabetes mellitus classified by plasma C-peptide: Fredericia survey of subjects 60-74 yr old.
    Damsgaard EM; Faber OK; Frøland A; Green A; Hauge M; Holm NV; Iversen S
    Diabetes Care; 1987; 10(1):26-32. PubMed ID: 3552511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects.
    Niskanen LK; Uusitupa MI; Sarlund H; Siitonen O; Pyörälä K
    Diabetes Care; 1990 Jan; 13(1):41-8. PubMed ID: 2404716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherosclerotic vascular disease in middle-aged, insulin-treated, diabetic patients. Association with endogenous insulin secretion capacity.
    Rönnemaa T; Laakso M; Puukka P; Kallio V; Pyörälä K
    Arteriosclerosis; 1988; 8(3):237-44. PubMed ID: 3285822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping insulin treatment in middle-aged diabetic patients with high postglucagon plasma C-peptide. Effect on glycaemic control, serum lipids and lipoproteins.
    Laakso M; Sarlund H; Korhonen T; Voutilainen E; Majander H; Hakala P; Uusitupa M; Pyörälä K
    Acta Med Scand; 1988; 223(1):61-8. PubMed ID: 3279723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal and postglucagon C-peptide levels in Ethiopians with diabetes.
    Siraj ES; Reddy SS; Scherbaum WA; Abdulkadir J; Hammel JP; Faiman C
    Diabetes Care; 2002 Mar; 25(3):453-7. PubMed ID: 11874929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients.
    Viikari J; Rönnemaa T; Koskinen P
    Ann Clin Res; 1987; 19(3):178-82. PubMed ID: 3314647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency.
    Prando R; Odetti P; Melga P; Giusti R; Ciuchi E; Cheli V
    Diabetes Metab; 1996 Jun; 22(3):185-91. PubMed ID: 8697306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men.
    Chen KW; Boyko EJ; Bergstrom RW; Leonetti DL; Newell-Morris L; Wahl PW; Fujimoto WY
    Diabetes Care; 1995 Jun; 18(6):747-53. PubMed ID: 7555498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-peptide response to meal challenge in nondiabetic and diabetic adults living in Wadena, Minnesota.
    Bushhouse SA; Goetz FC; Jacobs DR; Bender AP; French LR; Oestreich PG; Geisser MS
    Diabetes Care; 1992 Oct; 15(10):1335-47. PubMed ID: 1425099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes.
    Thomas NJ; Lynam AL; Hill AV; Weedon MN; Shields BM; Oram RA; McDonald TJ; Hattersley AT; Jones AG
    Diabetologia; 2019 Jul; 62(7):1167-1172. PubMed ID: 30969375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics.
    Kyllästinen M; Elfving S
    Gerontology; 1986; 32(6):317-26. PubMed ID: 3556328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics in the discrimination between patients with low or high C-peptide level among middle-aged insulin-treated diabetics.
    Laakso M; Sarlund H; Pyörälä K
    Diabetes Res; 1987 Feb; 4(2):95-9. PubMed ID: 3581663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glutamic acid decarboxylase autoantibodies (antiGAD-Ab) in patients with non-insulin dependent diabetes mellitus (NIDDM)].
    Martinka E; Straková J; Ocenásová A; Pullmannová D; Petrisková J; Mácková N; Sutarík L; Galajda P; Baláz D; Kerný J; Vladár L; Mokán M
    Vnitr Lek; 1998 Jan; 44(1):17-22. PubMed ID: 9750478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of plasma C-peptide determination in the management of type II diabetes.
    Aro A
    Acta Endocrinol Suppl (Copenh); 1985; 272():79-82. PubMed ID: 3914808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
    N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes.
    Nosari I; Lepore G; Maglio ML; Cortinovis F; Pagani G
    J Endocrinol Invest; 1992 Feb; 15(2):143-6. PubMed ID: 1569291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.